Mortality Outcome for Dexamethasone application - Clinical Practice Guidelines (CPG) on EBMonFHIR v1.0.2

Clinical Practice Guidelines (CPG) on EBMonFHIR
1.0.2 - ci-build

Clinical Practice Guidelines (CPG) on EBMonFHIR, published by Universitätsmedizin Greifswald. This guide is not an authorized publication; it is the continuous build for version 1.0.2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/CEOsys/cpg-on-ebm-on-fhir/ and changes regularly. See the Directory of published versions

Example Evidence: Mortality Outcome for Dexamethasone application

Active as of 2024-10-21

Generated Narrative: Evidence DexamethasoneOutcomeMortality

url: Evidence ExampleOutcomeEvidence

name: ExampleOutcomeEvidence

status: Active

experimental:

date: 2024-10-21 14:52:15+0000

copyright:

RelatedArtifacts

Type

ResourceReference

Citation

Citation SystemicCorticosteroidsForTheTreatmentOfCOVID19

variableDefinition
variableRole: population
observed: Group StudyCohortCriteriaSystemicCorticosteroidsCOVID19
intended: EvidenceVariable StudyEligibilityCriteriaSystemicCorticosteroidsCOVID19

variableDefinition
variableRole: measured variable
observed: EvidenceVariable AllCauseMortality

synthesisType: not applicable

statistic
description:
Relative effect of intervention vs. comparator

statisticType: Relative Risk
quantity: 0.89
SampleSizes
- NumberOfStudies NumberOfParticipants
* 9 7930
AttributeEstimates
- Type Level Range
* Confidence interval 0.95 0.8-1

statistic
description:
Baseline risk/result in the comparison group

statisticType: Incidence
quantity: 245 1/1000 (Details: UCUM code1/1000 = '1/1000')